Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche’s Ocrelizumab Poised To Seize Primary Progressive MS Opportunity

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche plans to file the selective CD20 antibody in 2016 after releasing positive Phase III data at ECTRIMS in both relapsing-remitting and primary progressive multiple sclerosis, a debilitating form of the disease for which there are no approved drugs.

Advertisement

Related Content

Ocrevus Launching Quickly Even After Manufacturing Worries Delayed US Approval
Roche’s Highly Anticipated Ocrelizumab Delayed By Manufacturing Issues
Keeping Track: FDA Approves Epclusa, Designates Four Breakthrough Therapies, Files Burst Of Applications
Roche: Slow And Steady Wins The Race
Roche CEO Warns Against 'Middle Ground' Approach To Combat Pricing Pressure
More Problems For Biogen's Tysabri
Deal Watch: Bristol Doubles Down On Five Prime, Roche Continues Diversifying
Teva Pins Long-Term Hopes In MS On The Return Of Laquinimod
Ocrelizumab May Represent Roche’s Rebound In Neuroscience
Despite Ocrelizumab Infection Risk, Roche Sees Multiple Sclerosis Opportunity

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077969

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel